Where is MeiraGTx located?

MeiraGTx is headquartered in New York City, United States.

How many employees does MeiraGTx have?

As of Dec 31, 2022, the latest employee count at MeiraGTx is 358.

Is MeiraGTx a funded company?

MeiraGTx is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of MeiraGTx?

MeiraGTx's latest funding was a $***** Post IPO round on Oct 30, 2023, with participation from 1 investor.

What is the annual revenue of MeiraGTx?

Annual revenue of MeiraGTx is $33.3M as on Dec 31, 2024.

Where does MeiraGTx rank among its competitors?

MeiraGTx ranks 72nd amongst 3566 active competitors, of which 1254 are funded. The most recent competitor to raise funding was Karyopharm, which secured $8.75M in Oct, 2025.

Who are the top competitors of MeiraGTx?

MeiraGTx's top competitors include Jazz Pharmaceuticals, Alnylam and C4 Therapeutics. Among them, Karyopharm secured the most recent funding round in October, 2025.

MeiraGTx - 2026 Company Profile, Team, Funding, Competitors & Financials

MeiraGTx is a public company based in New York City (United States), founded in 2015 by Sam Waksal. It operates as a Developer of gene therapies for ocular and neurodegenerative diseases. MeiraGTx has raised an undisclosed amount in funding. The company has 3566 active competitors, including 1254 funded and 860 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and C4 Therapeutics.

Company Details

Developer of gene therapies for ocular and neurodegenerative diseases. Its drug pipeline includes AAV-RPGR to treat the most common form of X-linked retinitis pigmentosa, AAV-RPE65 to treat rare pediatric disease, and AAV-GAD is an investigational gene therapy to treat Parkinson's disease.

Website: meiragtx.com
Social
Email ID: *****@meiragtx.com

Key Metrics

Founded Year

2015

Location

New York City, United States

Stage

Public

Latest Funding Round

Post IPO, Oct 30, 2023, $*****

Investors

Perceptive Advisors & 6 more

Ranked

72^nd among 3566 active competitors

Annual Revenue

$33.3M as on Dec 31, 2024

Employee Count

358 as on Dec 31, 2022

Similar Companies

Alnylam & 1565 more

Exit Details

Public

View MeiraGTx's full profile

MeiraGTx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MEIRAGTX HOLDINGS PLC CIN: 98-1448305 , United States, Active		$33.3M (As on Dec 31, 2024)	358 (As on Dec 31, 2022)	-

MeiraGTx got listed on Jun 08, 2018.

Click here to take a look at MeiraGTx's IPO in detail

MeiraGTx has raised funding over 3 rounds. Its latest funding round was a Post IPO round on Oct 30, 2023 for $*****. 1 investor participated in its latest round. MeiraGTx has 7 institutional investors.

Here is the list of recent funding rounds of MeiraGTx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 30, 2023	9205992	Post IPO	7285520	9400019	1404452	7129566
Feb 27, 2019	7519193	Post IPO	4019621	8647875	5953334	Perceptive Advisors & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of MeiraGTx's funding rounds and investors

The founders of MeiraGTx is Sam Waksal.

Here are the details of MeiraGTx's key team members:

Sam Waksal: Founder & CEO of MeiraGTx and founder of 1 other company.

View details of MeiraGTx's Founder profiles and Board Members

MeiraGTx's employee count trend

MeiraGTx has 358 employees as of Dec 22. The total employee count is 21.0% more than what it was in Dec 21. Here is MeiraGTx's employee count trend over the years:

Uncover MeiraGTx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MeiraGTx include Jazz Pharmaceuticals, Alnylam and C4 Therapeutics. Here is the list of Top 10 competitors of MeiraGTx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	KKR, Versant Ventures & 14 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Military Health, GUB & 13 others	77/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 25 others	76/100
4th	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	76/100
5th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Delphi Ventures & 15 others	75/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Children's Hospital of Philadelphia ... & 6 others	75/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	MPM Capital, Fidelity Investments & 19 others	74/100
8th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	74/100
9th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Ridgeback Capital Management ... & 14 others	74/100
10th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$806M	Fidelity Investments, Redmile Group & 28 others	73/100
72nd	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100